TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Eurofins Biopharma Product Testing Sweden AB
Closing information (x1000 EUR)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
6,084
|
5,550
|
5,487 |
| Financial expenses |
234
|
151
|
113 |
| Earnings before taxes |
-1,836
|
-1,889
|
-2,265 |
| EBITDA |
-1,166
|
-1,289
|
-1,652 |
| Total assets |
3,302
|
4,148
|
5,996 |
| Current assets |
1,898
|
2,338
|
4,127 |
| Current liabilities |
1,966
|
1,248
|
1,363 |
| Equity capital |
-1,682
|
150
|
1,815 |
| - share capital |
9
|
9
|
10 |
| Employees (average) |
46
|
50
|
60 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
-50.9%
|
3.6%
|
30.3% |
| Turnover per employee |
132
|
111
|
91 |
| Profit as a percentage of turnover |
-30.2%
|
-34.0%
|
-41.3% |
| Return on assets (ROA) |
-48.5%
|
-41.9%
|
-35.9% |
| Current ratio |
96.5%
|
187.3%
|
302.8% |
| Return on equity (ROE) |
109.2%
|
-1259.3%
|
-124.8% |
| Change turnover |
518
|
508
|
-455 |
| Change turnover % |
9%
|
10%
|
-8% |
| Chg. No. of employees |
-4
|
-10
|
8 |
| Chg. No. of employees % |
-8%
|
-17%
|
15% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.